Deoxycholic Acid
CAS 83-44-3
Deoxycholic Acid (CAS 83-44-3) is a Phase 4 pharmaceutical compound with 4 bioactivity targets and 26 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 41551.57344827586 nM | 58 | - |
| - | MIC | 1767.2651515151515 ug.mL-1 | 33 | - |
| - | AC50 | 29848.003333333334 nM | 30 | - |
| - | EC50 | 16544 nM | 10 | - |
| - | IC50 | 85166.66666666667 nM | 9 | - |
| - | Potency | 23724.875 nM | 8 | - |
| - | Kd | 16000 nM | 2 | - |
| - | Ki | 6300 nM | 1 | - |
| fMet-Leu-Phe receptor GPCR |
Ki | 4 | - | Homo sapiens |
| Bile acid receptor Nuclear hormone receptor |
EC50 | 4.35 | - | Homo sapiens |
| G-protein coupled bile acid receptor 1 GPCR |
EC50 | 6.2 | - | Homo sapiens |
| Steroid Delta-isomerase Unclassified |
Kd | 4.8 | - | Pseudomonas putida |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Injection site swelling | 123 | 469.51 | 10053425 |
| Facial paresis | 58 | 301.671 | 10051267 |
| Injection site nodule | 54 | 285.63 | 10057880 |
| Nerve injury | 55 | 244.063 | 10052897 |
| Swelling | 113 | 227.92 | 10042674 |
| Injection site pain | 86 | 209.032 | 10022086 |
| Injection site induration | 40 | 169.181 | 10022075 |
| Injection site mass | 43 | 154.852 | 10022081 |
| Injection site hypoaesthesia | 22 | 142.695 | 10074586 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| FPR1 FPR1 |
Antagonist | 4.0 pKi | 11853704 |
| Farnesoid X receptor | Agonist | 4.0 pEC50 | 7898771|10334993|10360171 |
| GPBA receptor GPBAR1 |
Full agonist | 6.2 pEC50 | 12419312 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| DEOXYCHOLIC ACID | 3194 | SU | MTHSPL |
| deoxycholic acid | 3194 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Deoxycholic Acid used for in pharmaceutical contexts?
Deoxycholic Acid (CAS 83-44-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Deoxycholic Acid?
Deoxycholic Acid has 26 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Injection site swelling, Facial paresis, Injection site nodule, Nerve injury, Swelling. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Deoxycholic Acid also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Deoxycholic Acid with EU status "prohibited".
What clinical phase is Deoxycholic Acid in?
Deoxycholic Acid is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Deoxycholic Acid?
Deoxycholic Acid has 12 bioactivity rows in this page query. Rendered target entries include fMet-Leu-Phe receptor, Bile acid receptor, G-protein coupled bile acid receptor 1, Steroid Delta-isomerase.